Early therapy with neuraminidase inhibitors for influenza A (H1N1) pdm 2009 infection

被引:5
|
作者
Yamamoto, Takehisa [1 ]
Ihashi, Mai [1 ]
Mizoguchi, Yoshimi [1 ]
Kaneno, Hiroshi [1 ]
Yamamoto, Katsusuke [1 ]
Inoue, Yutaka [2 ]
Kase, Tetsuo [3 ]
Okabe, Nobuhiko [4 ]
Shimotsuji, Tsunesuke [1 ]
机构
[1] Minoh City Hosp, Dept Pediat, Minoh City, Osaka 5628562, Japan
[2] Minoh City Hosp, Dept Radiol, Minoh City, Osaka 5628562, Japan
[3] Osaka Prefectural Inst Publ Hlth, Osaka 537, Japan
[4] Kawasaki City Inst Publ Hlth, Kawasaki, Kanagawa 2100834, Japan
关键词
early therapy; estimated clinical severity; influenza A (H1N1) pdm 2009; mean covariance structure equation analysis; neuraminidase inhibitor; OSELTAMIVIR TREATMENT; CLINICAL-FEATURES; JAPAN ANALYSIS; A(H1N1); OUTCOMES; IMPACT; VIRUS;
D O I
10.1111/ped.12154
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
BackgroundNeuraminidase inhibitors have been reported to decrease mortality in patients infected with influenza A (H1N1) pdm 2009 (H1N1pdm09), but it is not clear whether they are effective againstH1N1pdm09 in apparently healthy children. MethodsThe effect of early treatment with neuraminidase inhibitors on 70 otherwise healthy children with possible H1N1pdm09 (pH1N1pdm09) infection was investigated. The children were simultaneously treated with a neuraminidase inhibitor (oseltamivir or zanamivir) and maoto, a Japanese traditional herbal medicine, which had been reported to be effective against seasonal influenza. Clinical severity was assessed using patient history, namely the worst values for clinical vital signs and laboratory data on admission. After refining these parameters with univariate, decision tree and multiple regression analysis, mean covariance structure equation analysis was used to investigate the association of estimated clinical severity to the selected parameters. ResultsTotal path analysis using a Bayesian method indicated that the estimated clinical severity of pH1N1pdm09 was positively associated with maximum body temperature, pulse rate, respiration rate, duration necessary for defervescence, admission duration and log urinary 2-microglobulin/creatinine level, and negatively associated with age and the presence and duration of treatment with the neuraminidase inhibitor in the outpatient clinic. ConclusionsThis study provides the first clinical evidence that early treatment with neuraminidase inhibitors in outpatient clinic decreased the estimated clinical severity of pH1N1pdm09 in apparently otherwise healthy pediatric inpatients.
引用
收藏
页码:714 / 721
页数:8
相关论文
共 50 条
  • [1] Treatment With Neuraminidase Inhibitors for Critically Ill Patients With Influenza A (H1N1) pdm09
    Louie, Janice K.
    Yang, Samuel
    Acosta, Meileen
    Yen, Cynthia
    Samuel, Michael C.
    Schechter, Robert
    Guevara, Hugo
    Uyeki, Timothy M.
    CLINICAL INFECTIOUS DISEASES, 2012, 55 (09) : 1198 - 1204
  • [2] Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors
    Delgado-Rodriguez, Miguel
    Castilla, Jesus
    Godoy, Pere
    Martin, Vicente
    Soldevila, Nuria
    Alonso, Jordi
    Astray, Jenaro
    Baricot, Maretva
    Canton, Rafael
    Castro, Ady
    Gonzalez-Candelas, Fernando
    Maria Mayoral, Jose
    Maria Quintana, Jose
    Pumarola, Tomas
    Tamames, Sonia
    Saez, Marc
    Dominguez, Angela
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (07) : 1739 - 1745
  • [3] Antibody responses to influenza A(H1N1)pdm infection
    Wraith, Steph
    Nachbagauer, Raffael
    Balmaseda, Angel
    Stadlbauer, Daniel
    Ojeda, Sergio
    Rajabhathor, Arvind
    Lopez, Roger
    Guglia, Andrea F.
    Sanchez, Nery
    Amanat, Fatima
    Gresh, Lionel
    Kuan, Guillermina
    Krammer, Florian
    Gordon, Aubree
    VACCINE, 2020, 38 (27) : 4221 - 4225
  • [4] Influenza A (H1N1) neuraminidase inhibitors from Vitis amurensis
    Nguyen, Thi Ngoc Anh
    Dao, Trong Tuan
    Tung, Bui Thanh
    Choi, Hwanwon
    Kim, Eunhee
    Park, Junsoo
    Lim, Seong-Il
    Oh, Won Keun
    FOOD CHEMISTRY, 2011, 124 (02) : 437 - 443
  • [5] Neuraminidase inhibitors were widely used in the UK during the 2009 influenza A(H1N1) pandemic
    Nguyen-Van-Tam, Jonathan S.
    Nicholson, Karl G.
    JOURNAL OF CLINICAL VIROLOGY, 2011, 50 (02) : 183 - 183
  • [6] Immunopathology Of The Airways In Severe Influenza A (H1N1) pdm Infection
    Buttignol, M.
    Pires-Neto, R. C.
    Rossi E Silva, R. C.
    Ballarin, M.
    Dolhnikoff, M.
    Mauad, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [7] Peramivir: An Intravenous Neuraminidase Inhibitor for the Treatment of 2009 H1N1 Influenza
    Mancuso, Carissa E.
    Gabay, Michael P.
    Steinke, Leah M.
    VanOsdol, Sherilyn J.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (7-8) : 1240 - 1249
  • [8] QSAR Study of H1N1 Neuraminidase Inhibitors from Influenza a Virus
    Worachartcheewan, Apilak
    Nantasenamat, Chanin
    Isarankura-Na-Ayudhya, Chartchalerm
    Prachayasittikul, Virapong
    LETTERS IN DRUG DESIGN & DISCOVERY, 2014, 11 (04) : 420 - 427
  • [9] French general practitioners' perceptions and use of neuraminidase inhibitors during the pandemic A(H1N1)2009 influenza
    Barthe, Juliette
    Noyelle, Clemence
    Partouche, Henri
    SANTE PUBLIQUE, 2011, 23 (04): : 305 - 315
  • [10] Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007-2008 and 2008-2009 seasons
    Kawai, Naoki
    Ikematsu, Hideyuki
    Tanaka, Osame
    Matsuura, Shinro
    Maeda, Tetsunari
    Yamauchi, Satoshi
    Hirotsu, Nobuo
    Nishimura, Mika
    Iwaki, Norio
    Kashiwagi, Seizaburo
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2011, 17 (03) : 375 - 381